



Advanced Control Formulary™ Change Summary Report Effective 01-01-2019

This report highlights all changes (additions, deletions, and removals) to the CVS Caremark® Advanced Control Formulary.

ADDITIONS:

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Brand Agents:			
Accu-Chek Aviva Plus, Accu-Chek Compact Plus, Accu-Chek Guide, Accu-Chek SmartView Strips and Kits blood glucose test strips, monitoring kits	Endocrine and Metabolic/ Antidiabetics/ Supplies	Accu-Chek strips and kits are used to test and monitor blood glucose levels in those who have diabetes.	To provide an option for testing and monitoring blood glucose levels.
Adynovate (antihemophilic factor [recombinant] pegylated) IV solution for injection	Hematologic/ Hemophilia A Agents	Adynovate is indicated in children and adults with hemophilia A (congenital factor VIII deficiency) for: <ul style="list-style-type: none"> • On-demand treatment and control of bleeding episodes. • Perioperative management. • Routine prophylaxis to reduce the frequency of bleeding episodes. 	To provide an additional option for the treatment of hemophilia A.
Aralast NP (alpha ₁ -proteinase inhibitor) IV solution for injection	Respiratory/ Pulmonary Enzyme Deficiency Agents	Aralast NP is indicated for chronic augmentation therapy in adults with clinically evident emphysema due to	To provide an option for the treatment of emphysema due to an inherited disorder known as alpha ₁ -antitrypsin deficiency.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.
©2018 CVS Caremark. All rights reserved.

Advanced Control Formulary™ Change Summary Report Effective 01-01-2019

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		severe congenital deficiency of Alpha ₁ -proteinase inhibitor (alpha ₁ -antitrypsin deficiency).	
Arnuity Ellipta (fluticasone) breath-activated aerosol	Respiratory/ Steroid Inhalants	Arnuity Ellipta is indicated for once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 5 years and older.	To provide an additional prophylactic option for the treatment of asthma.
Copaxone 20 mg (glatiramer acetate) subcutaneous solution for injection	Central Nervous System/ Multiple Sclerosis Agents	Copaxone is indicated for the treatment of patients with relapsing-forms of multiple sclerosis.	To provide an additional option for the treatment of multiple sclerosis.
Durolane (sodium hyaluronate) intraarticular injection	Analgesics/ Viscosupplements	Durolane is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics (e.g., acetaminophen).	To provide an additional option for the treatment of knee pain due to osteoarthritis (OA).
Embeda (morphine-naltrexone) oral extended-release capsule	Analgesics/ Opioid Analgesics	Embeda is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.	To provide an additional option for the treatment of severe pain.
Erleada (apalutamide) oral tablet	Antineoplastic Agents/ Hormonal Antineoplastic Agents/ Antiandrogens	Erleada is indicated for the treatment of patients with non-	To provide an additional option for the treatment of prostate cancer.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.
©2018 CVS Caremark. All rights reserved.

Advanced Control Formulary™ Change Summary Report Effective 01-01-2019

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		metastatic castration-resistant prostate cancer.	
Eucrisa (crisaborole) topical ointment	Topical/ Dermatology/ Atopic Dermatitis/ Topical	Eucrisa is indicated for topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.	To provide an additional option for the treatment of atopic dermatitis.
Glassia (alpha ₁ -proteinase inhibitor) IV solution for injection	Respiratory/ Pulmonary Enzyme Deficiency Agents	Glassia indicated for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe hereditary deficiency of Alpha ₁ -proteinase inhibitor (alpha ₁ -antitrypsin deficiency).	To provide an option for the treatment of emphysema due to an inherited disorder known as alpha ₁ -antitrypsin deficiency.
Glyxambi (empagliflozin-linagliptin) oral tablet	Endocrine and Metabolic/ Antidiabetics/ Sodium-Glucose Co- Transporter 2 (SGLT2) Inhibitor / Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Combinations	Glyxambi is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate.	To provide an additional option to improve glycemic control in adults with type 2 diabetes mellitus.
Jardiance (empagliflozin) oral tablet	Endocrine and Metabolic/ Antidiabetics/ Sodium-Glucose Co- Transporter 2 (SGLT2) Inhibitors	Jardiance is indicated: <ul style="list-style-type: none"> • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • To reduce the risk of cardiovascular death in adult 	To provide an additional option to improve glycemic control in adults with type 2 diabetes mellitus.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2018 CVS Caremark. All rights reserved.

Advanced Control Formulary™ Change Summary Report Effective 01-01-2019

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		patients with type 2 diabetes mellitus and established cardiovascular disease.	
Jivi (antihemophilic factor [recombinant] pegylated-auct) IV solution for injection	Hematologic/ Hemophilia A Agents	Jivi is indicated for use in previously treated adults and adolescents (12 years of age and older) with hemophilia A (congenital Factor VIII deficiency) for: <ul style="list-style-type: none"> • On-demand treatment and control of bleeding episodes. • Perioperative management of bleeding. • Routine prophylaxis to reduce the frequency of bleeding episodes. 	To provide an additional option for the treatment of hemophilia A.
Nucala (mepolizumab) subcutaneous solution for injection	Respiratory/ Severe Asthma Agents	Nucala is indicated for: <ul style="list-style-type: none"> • Add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. • The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 	To provide an option for the treatment of severe asthma or eosinophilic granulomatosis with polyangiitis (EGPA).
Prolastin-C (alpha ₁ -proteinase inhibitor) IV solution for injection	Respiratory/ Pulmonary Enzyme Deficiency Agents	Prolastin-C is indicated for chronic augmentation and maintenance therapy in adults with clinical	To provide an option for the treatment of emphysema due to an inherited disorder known as alpha ₁ -antitrypsin deficiency.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.
©2018 CVS Caremark. All rights reserved.

Advanced Control Formulary™ Change Summary Report Effective 01-01-2019

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		evidence of emphysema due to severe hereditary deficiency of Alpha ₁ -proteinase inhibitor (alpha ₁ -antitrypsin deficiency).	
Rebinyn (coagulation factor IX [recombinant] glycopegylated) IV solution for injection	Hematologic/ Hemophilia B Agents	Rebinyn is indicated for use in adults and children with hemophilia B for: <ul style="list-style-type: none"> • On-demand treatment and control of bleeding episodes. • Perioperative management of bleeding. 	To provide an option for the treatment of hemophilia B.
Rhopressa (netarsudil) ophthalmic solution	Topical/ Ophthalmic/ Rho Kinase Inhibitors	Rhopressa is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.	To provide an additional option for the treatment of open-angle glaucoma or ocular hypertension.
Synjardy (empagliflozin-metformin) oral tablet	Endocrine and Metabolic/ Antidiabetics/ Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor / Biguanide Combinations	Synjardy is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin hydrochloride is appropriate.	To provide an additional option to improve glycemic control in adults with type 2 diabetes mellitus.
Synjardy XR (empagliflozin-metformin ext-rel) oral extended-release tablet	Endocrine and Metabolic/ Antidiabetics/ Sodium-Glucose Co-Transporter 2 (SGLT2)	Synjardy XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin	To provide an additional option to improve glycemic control in adults with type 2 diabetes mellitus.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.
©2018 CVS Caremark. All rights reserved.

Advanced Control Formulary™ Change
 Summary Report
 Effective 01-01-2019

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
	Inhibitor / Biguanide Combinations	and metformin hydrochloride is appropriate.	
Zejula (niraparib) oral capsule	Antineoplastic Agents/ Miscellaneous	Zejula is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.	To provide an option for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Generic Agents:			
colesevelam oral packet, oral tablet	Cardiovascular/ Antilipemics/ Bile Acid Resins	Colesevelam is indicated as an adjunct to diet and exercise to: <ul style="list-style-type: none"> • Reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia as monotherapy or in combination with a hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin). • Reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia as monotherapy or in combination 	To provide an additional generic option for the treatment of high cholesterol.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.
 ©2018 CVS Caremark. All rights reserved.

Advanced Control Formulary™ Change Summary Report Effective 01-01-2019

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		with a statin after failing an adequate trial of diet therapy. <ul style="list-style-type: none"> Improve glycemic control in adults with type 2 diabetes mellitus. 	

DELETIONS:

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Brand Agents:			
Lupron Depot 3.75 mg (leuprolide acetate) intramuscular suspension for injection	Antineoplastic Agents/ Hormonal Antineoplastic Agents/ Luteinizing Hormone-Releasing Hormone (LHRH) Agonists	Lupron Depot is indicated for: <ul style="list-style-type: none"> Management of endometriosis, including pain relief and reduction of endometriotic lesions. The preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata (fibroids). 	Availability of additional options for the management of endometriosis and uterine leiomyomata (fibroids). Consult doctor for preferred options on the Advanced Control Formulary.
Lupron Depot 11.25 mg (leuprolide acetate) intramuscular suspension for injection	Antineoplastic Agents/ Hormonal Antineoplastic Agents/ Luteinizing Hormone-Releasing	Lupron Depot is indicated for: <ul style="list-style-type: none"> Management of endometriosis, including pain relief and reduction of endometriotic lesions. 	Availability of additional options for the management of endometriosis and uterine leiomyomata (fibroids). Consult doctor for preferred options on the Advanced Control Formulary.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.
©2018 CVS Caremark. All rights reserved.

Advanced Control Formulary™ Change
 Summary Report
 Effective 01-01-2019

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
	Hormone (LHRH) Agonists	<ul style="list-style-type: none"> In combination with a norethindrone acetate 5 mg tablet taken once daily as add-back therapy: initial management of the painful symptoms of endometriosis and for the management of recurrence of symptoms. Concomitant use with iron therapy for preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata (fibroids). 	
Welchol (colesevelam) oral packet, oral tablet	Cardiovascular/ Antilipemics/ Bile Acid Resins	<p>Welchol is indicated as an adjunct to diet and exercise to:</p> <ul style="list-style-type: none"> Reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia as monotherapy or in combination with a hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin). Reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial 	<p>Availability of generic options for the treatment of high cholesterol.</p> <p>The preferred options on the Advanced Control Formulary include cholestyramine and colesevelam.</p>

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.
 ©2018 CVS Caremark. All rights reserved.

Advanced Control Formulary™ Change Summary Report Effective 01-01-2019

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy. <ul style="list-style-type: none"> • Improve glycemic control in adults with type 2 diabetes mellitus. 	
Zoladex 3.6 mg (goserelin acetate) subcutaneous implant	Antineoplastic Agents/ Hormonal Antineoplastic Agents/ Luteinizing Hormone-Releasing (LHRH) Agonists	Zoladex is indicated for: <ul style="list-style-type: none"> • Use in combination with flutamide for the management of locally confined carcinoma of the prostate. • Palliative treatment of advanced carcinoma of the prostate. • The management of endometriosis. • Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding. • Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women. 	Availability of additional options for the treatment of prostate cancer, endometriosis, endometrial-thinning prior to endometrial ablation, or advanced breast cancer. The preferred option on the Advanced Control Formulary for prostate cancer is Eligard (leuprolide acetate). Consult doctor for preferred options on the Advanced Control Formulary for endometriosis and advanced breast cancer.
Zoladex 10.8 mg (goserelin acetate) subcutaneous implant	Antineoplastic Agents/ Hormonal Antineoplastic Agents/ Luteinizing	Zoladex is indicated for: <ul style="list-style-type: none"> • Use in combination with flutamide for the management 	Availability of an additional option for the treatment of prostate cancer.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.
©2018 CVS Caremark. All rights reserved.

Advanced Control Formulary™ Change Summary Report Effective 01-01-2019

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
	Hormone-Releasing (LHRH) Agonists	<p>of locally confined carcinoma of the prostate.</p> <ul style="list-style-type: none"> Use as palliative treatment of advanced carcinoma of the prostate. 	The preferred option on the Advanced Control Formulary for prostate cancer is Eligard (leuprolide acetate).

REMOVALS:

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Brand Agents:			
Acanya (clindamycin-benzoyl peroxide) topical gel	Topical/ Dermatology/ Acne/ Topical	Acanya is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.	<p>Availability of additional options for the topical treatment of acne.</p> <p>Preferred options on the Advanced Control Formulary include adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, Atralin (tretinoin), Differin Cream (adapalene), Differin Gel 0.3% (adapalene), Differin Lotion (adapalene), Epiduo (adapalene-benzoyl peroxide), Retin-A Micro (tretinoin gel microsphere), and Tazorac (tazarotene).</p>
Alprolix (coagulation factor IX [recombinant] Fc fusion protein)	Hematologic/ Hemophilia B Agents	Alprolix is indicated in adults and children with hemophilia B for:	Availability of additional management options for adults and children with hemophilia B.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.
©2018 CVS Caremark. All rights reserved.

Advanced Control Formulary™ Change Summary Report Effective 01-01-2019

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
IV solution for injection		<ul style="list-style-type: none"> • On-demand treatment and control of bleeding episodes. • Perioperative management of bleeding. • Routine prophylaxis to reduce the frequency of bleeding episodes. 	Consult doctor for preferred options on the Advanced Control Formulary.
Avenova (hypochlorous acid eyelid cleanser) topical solution	Topical/ Ophthalmic/ Miscellaneous	Avenova is designed for removal of microorganisms and debris that contribute to these conditions such as dry eye, meibomian glands dysfunction (MGD), blepharitis, meibomitis, eye allergies, and stye.	<p>Availability of additional options for eyelid cleansing and removal of microorganism and debris.</p> <p>Consult doctor for preferred options on the Advanced Control Formulary.</p>
BenzaClin (clindamycin-benzoyl peroxide) topical gel	Topical/ Dermatology/ Acne/ Topical	BenzaClin is indicated for the topical treatment of acne vulgaris.	<p>Availability of additional options for the topical treatment of acne.</p> <p>Preferred options on the Advanced Control Formulary include adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, Atralin (tretinoin), Differin Cream (adapalene), Differin Gel 0.3% (adapalene), Differin Lotion (adapalene), Epiduo (adapalene-benzoyl peroxide), Retin-A Micro (tretinoin gel microsphere), and Tazorac (tazarotene).</p>
Cambia (diclofenac potassium)	Analgesics/ NSAIDs	Cambia is indicated for the acute treatment of migraine attacks with or	Availability of generic nonsteroidal anti-inflammatory agents (NSAIDs) for treating migraines.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.
©2018 CVS Caremark. All rights reserved.

Advanced Control Formulary™ Change Summary Report Effective 01-01-2019

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
oral packet		without aura in adults 18 years of age or older.	Preferred options on the Advanced Control Formulary include diclofenac sodium, ibuprofen, meloxicam, and naproxen.
Cimzia (certolizumab) subcutaneous injection	Immunologic Agents/ Autoimmune Agents	Cimzia is indicated for: <ul style="list-style-type: none"> • Treatment of adults with active ankylosing spondylitis (AS). • Reducing signs and symptoms of Crohn's disease (CD) and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. • Treatment of adults with moderate-to-severe plaque psoriasis (Ps) who are candidates for systemic therapy or phototherapy. • Treatment of adult patients with active psoriatic arthritis (PsA). • Treatment of adults with moderately to severely active rheumatoid arthritis (RA). 	Availability of additional options for the treatment of ankylosing spondylosis (AS), Crohn's Disease (CD), psoriasis (Ps), psoriatic arthritis (PsA), and rheumatoid arthritis (RA). Preferred options on the Advanced Control Formulary include: <ul style="list-style-type: none"> • Ankylosing spondylosis (AS): Cosentyx (secukinumab), Enbrel (etanercept), and Humira (adalimumab) • Crohn's Disease (CD): Humira (adalimumab) and Stelara Subcutaneous (ustekinumab)¹ • Psoriasis (Ps): Humira (adalimumab), Otezla (apremilast), Stelara Subcutaneous (ustekinumab), and Taltz (ixekizumab) • Psoriatic Arthritis (PsA): Cosentyx (secukinumab), Enbrel (etanercept), Humira (adalimumab), Otezla (apremilast) • Rheumatoid Arthritis (RA): Enbrel (etanercept), Humira (adalimumab), Kevzara (sarilumab), Orencia ClickJect (abatacept), Orencia Subcutaneous (abatacept), Xeljanz (tofacitinib), and Xeljanz XR (tofacitinib) 1. After failure of Humira (adalimumab)
Eloctate (antihemophilic factor [recombinant] Fc fusion protein)	Hematologic/ Hemophilia A Agents	Eloctate is indicated in adults and children with Hemophilia A	Availability of additional management options for adults and children with hemophilia A.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.
©2018 CVS Caremark. All rights reserved.

Advanced Control Formulary™ Change Summary Report Effective 01-01-2019

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
IV solution for injection		(congenital Factor VIII deficiency) for: <ul style="list-style-type: none"> • On-demand treatment and control of bleeding episodes. • Perioperative management of bleeding. • Routine prophylaxis to reduce the frequency of bleeding episodes. 	Preferred options on the Advanced Control Formulary include Adynovate (antihemophilic factor [recombinant] pegylated), Jivi (antihemophilic factor [recombinant] pegylated-aucl), Kogenate FS (antihemophilic factor [recombinant]), Kovaltry (antihemophilic factor [recombinant]), Novoeight (antihemophilic factor [recombinant]), and Nuwiq (antihemophilic factor [recombinant]).
Fasenra (benralizumab) subcutaneous solution for injection	Respiratory/ Severe Asthma Agents	Fasenra is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.	Availability of an additional maintenance option for severe asthma with an eosinophilic phenotype. The preferred option on the Advanced Control Formulary is Nucala (mepolizumab).
Invokamet (canagliflozin-metformin) oral tablet	Endocrine and Metabolic/ Antidiabetics/ Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor / Biguanide Combinations	Invokamet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both canagliflozin and metformin is appropriate.	Availability of additional options for the treatment of type 2 diabetes mellitus. Preferred options on the Advanced Control Formulary include Synjardy (empagliflozin-metformin), Synjardy XR (empagliflozin-metformin ext-rel), and Xigduo XR (dapagliflozin-metformin ext-rel).
Invokamet XR (canagliflozin-metformin ext-rel) oral extended-release tablet	Endocrine and Metabolic/ Antidiabetics/ Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor / Biguanide Combinations	Invokamet XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both canagliflozin and metformin is appropriate.	Availability of additional options for the treatment of type 2 diabetes mellitus. Preferred options on the Advanced Control Formulary include Synjardy (empagliflozin-metformin), Synjardy XR

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.
©2018 CVS Caremark. All rights reserved.

Advanced Control Formulary™ Change Summary Report Effective 01-01-2019

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
			(empagliflozin-metformin ext-rel), and Xigduo XR (dapagliflozin-metformin ext-rel).
Invokana (canagliflozin) oral tablet	Endocrine and Metabolic/ Antidiabetics/ Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors	Invokana is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.	Availability of additional options for the treatment of type 2 diabetes mellitus. Preferred options on the Advanced Control Formulary include <u>Farxiga (dapagliflozin)</u> and <u>Jardiance (empagliflozin)</u> .
Jentadueto (linagliptin-metformin) oral tablet	Endocrine and Metabolic/ Dipeptidyl Peptidase-4 (DPP-4) Inhibitor/Biguanide Combinations	Jentadueto is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.	Availability of additional options for the treatment of type 2 diabetes mellitus. Preferred options on the Advanced Control Formulary include <u>Janumet (sitagliptin-metformin)</u> and <u>Janumet XR (sitagliptin-metformin ext-rel)</u> .
Jentadueto XR (linagliptin-metformin ext-rel) oral extended-release tablet	Endocrine and Metabolic/ Dipeptidyl Peptidase-4 (DPP-4) Inhibitor/Biguanide Combinations	Jentadueto XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.	Availability of additional options for the treatment of type 2 diabetes mellitus. Preferred options on the Advanced Control Formulary include <u>Janumet (sitagliptin-metformin)</u> and <u>Janumet XR (sitagliptin-metformin ext-rel)</u> .
Lupron Depot 7.5 mg, 22.5 mg, 30 mg, 45 mg (leuprolide acetate) intramuscular suspension for injection	Antineoplastic Agents/ Hormonal Antineoplastic Agents/ Luteinizing Hormone-Releasing Hormone (LHRH) Agonists	Lupron Depot is indicated for palliative treatment of advanced prostatic cancer.	Availability of an additional option for the treatment of advanced prostatic cancer. The preferred option on the Advanced Control Formulary is <u>Eligard (leuprolide acetate)</u> .

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.
©2018 CVS Caremark. All rights reserved.

Advanced Control Formulary™ Change Summary Report Effective 01-01-2019

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
OneTouch Ultra, OneTouch Verio Strips and Kits blood glucose test strips, monitoring kits	Endocrine and Metabolic/ Antidiabetics/ Supplies	OneTouch Ultra and OneTouch Verio strips and kits are used to test and monitor blood glucose levels in those who have diabetes.	Availability of additional options for testing and monitoring blood glucose levels. Preferred options on the Advanced Control Formulary include Accu-Chek Aviva Plus strips and kits, Accu-Chek Compact Plus strips and kits, Accu-Chek Guide strips and kits, and Accu-Chek SmartView strips and kits.
Sorilux (calcipotriene) topical foam	Topical/ Dermatology/ Antipsoriatics	Sorilux is indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 18 years and older.	Availability of a generic option for the treatment of plaque psoriasis. The preferred option on the Advanced Control Formulary is calcipotriene.
TargaDOX (doxycycline hyclate) oral tablet	Anti-Infectives/ Antibacterials/ Tetracyclines	Targadox is indicated for the treatment of various infections.	Availability of a generic antibiotic option for the treatment of infections. The preferred option on the Advanced Control Formulary is doxycycline hyclate.
Tirosint (levothyroxine) oral capsule	Endocrine and Metabolic/ Thyroid Agents/ Thyroid Supplements	Tirosint is indicated for adults and pediatric patients 6 years and older with: <ul style="list-style-type: none"> • Hypothyroidism - As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) 	Availability of a generic option for the treatment of hypothyroidism. The preferred option on the Advanced Control Formulary is levothyroxine.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.
 ©2018 CVS Caremark. All rights reserved.

Advanced Control Formulary™ Change Summary Report Effective 01-01-2019

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		Suppression - As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.	
Tradjenta (linagliptin) oral tablet	Endocrine and Metabolic/ Dipeptidyl Peptidase-4 (DPP-4) Inhibitors	Tradjenta is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.	Availability of additional options for the treatment of type 2 diabetes mellitus. The preferred option on the Advanced Control Formulary is Januvia (sitagliptin).
Vanatol S (butalbital-acetaminophen-caffeine) oral syrup	Analgesics/ Non-Opioid Analgesics	Vanatol S is indicated for the relief of the symptom complex of tension (or muscle contraction) headache.	Availability of generic options for the relief of tension headache. Preferred options on the Advanced Control Formulary include diclofenac sodium, ibuprofen, and naproxen.
Zemaira (alpha ₁ -proteinase inhibitor) IV solution for injection	Respiratory/ Pulmonary Enzyme Deficiency Agents	Zemaira is indicated for chronic augmentation and maintenance therapy in adults with Alpha ₁ -proteinase inhibitor (alpha ₁ -antitrypsin deficiency) and clinical evidence of emphysema.	Availability of additional options for the treatment of emphysema due to an inherited disorder known as alpha ₁ -antitrypsin deficiency. Preferred options on the Advanced Control Formulary include Aralast NP (alpha ₁ -proteinase inhibitor), Glassia (alpha ₁ -proteinase inhibitor), and Prolastin-C (alpha ₁ -proteinase inhibitor).
Ziana (clindamycin-tretinoin) topical gel	Topical/ Dermatology/ Acne/ Topical	Ziana is indicated for the topical treatment of acne vulgaris in patients 12 years or older.	Availability of additional options for the topical treatment of acne.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.
©2018 CVS Caremark. All rights reserved.

Advanced Control Formulary™ Change
 Summary Report
 Effective 01-01-2019

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
			Preferred options on the Advanced Control Formulary include adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, Atralin (tretinoin), Differin Cream (adapalene), Differin Gel 0.3% (adapalene), Differin Lotion (adapalene), Epiduo (adapalene-benzoyl peroxide), Retin-A Micro (tretinoin gel microsphere), and Tazorac (tazarotene).
Zuplenz (ondansetron) oral film	Gastrointestinal/ Antiemetics	Zuplenz is indicated for: <ul style="list-style-type: none"> • Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy. • Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. • Prevention of nausea and vomiting associated with radiotherapy in patients receiving total body irradiation, single high-dose fraction to abdomen, or daily fractions to the abdomen. • Prevention of postoperative nausea and/or vomiting. 	Availability of generic options for the prevention of nausea and vomiting. Preferred options on the Advanced Control Formulary include granisetron and ondansetron.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.
 ©2018 CVS Caremark. All rights reserved.

OTHER:

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Brand Agents:			
Otezla (apremilast) oral tablet	Immunologic Agents/ Autoimmune Agents	Otezla is indicated for the treatment of: <ul style="list-style-type: none"> • Adult patients with active psoriatic arthritis (PsA). • Patients with moderate to severe plaque psoriasis (Ps) who are candidates for phototherapy or systemic therapy. 	Now preferred for psoriasis (Ps). Note: Otezla remains preferred for psoriatic arthritis (PsA).
Stelara Subcutaneous (ustekinumab) subcutaneous solution for injection	Immunologic Agents/ Autoimmune Agents	Stelara is indicated for the treatment of: <u>Adult patients with:</u> <ul style="list-style-type: none"> • Moderate to severe plaque psoriasis (Ps) who are candidates for phototherapy or systemic therapy. • Active psoriatic arthritis (PsA), alone or in combination with methotrexate. • Moderately to severely active Crohn's disease (CD) who have 	Now preferred for Crohn's Disease (CD) after failure of Humira (adalimumab). Also now preferred for Psoriasis (Ps) without failure of Humira (adalimumab). Note: Stelara Subcutaneous remains excluded for psoriatic arthritis (PsA).

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.
 ©2018 CVS Caremark. All rights reserved.

Advanced Control Formulary™ Change Summary Report Effective 01-01-2019

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		<ul style="list-style-type: none"> ○ Failed or were intolerant to treatment with immunomodulators or corticosteroids, but never failed a tumor necrosis factor (TNF) blocker or ○ Failed or were intolerant to treatment with one or more TNF blockers. <p><u>Adolescent patients (12 years or older) with:</u> Moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy.</p>	
Taltz (ixekizumab) subcutaneous solution for injection	Immunologic Agents/ Autoimmune Agents	Taltz is indicated for the treatment of adults with: <ul style="list-style-type: none"> ● Moderate-to-severe plaque psoriasis (Ps) who are candidates for systemic therapy or phototherapy. ● Active psoriatic arthritis (PsA). 	Now preferred for Psoriasis (Ps) without failure of Humira (adalimumab). Note: Taltz remains excluded for psoriatic arthritis (PsA).
Xeljanz (tofacitinib) oral immediate-release tablet	Immunologic Agents/ Autoimmune Agents	Xeljanz is indicated for the treatment of adults with: <ul style="list-style-type: none"> ● Moderately to severely active rheumatoid arthritis (RA) who have had an inadequate 	Now preferred for rheumatoid arthritis (RA). Note:

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.
©2018 CVS Caremark. All rights reserved.

Advanced Control Formulary™ Change Summary Report Effective 01-01-2019

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		response or intolerance to methotrexate <ul style="list-style-type: none"> • Active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs) • Moderately to severely active ulcerative colitis (UC). 	Xeljanz remains excluded for psoriatic arthritis (PsA) and ulcerative colitis (UC).
Xeljanz XR (tofacitinib ext-rel) oral extended-release tablet	Immunologic Agents/ Autoimmune Agents	Xeljanz XR is indicated for the treatment of adults with: <ul style="list-style-type: none"> • Moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate • Active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). 	Now preferred for rheumatoid arthritis (RA). Note: Xeljanz remains excluded for psoriatic arthritis (PsA).

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.
©2018 CVS Caremark. All rights reserved.